GenDx
Netherlands - UtrechtBiotechnology
Focus: GenDx specializes in HLA typing via next-generation sequencing, a niche diagnostic capability serving transplantation and immunology markets. The company operates as a focused biotech player based in Utrecht, Netherlands with a lean operational footprint.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About GenDx
AI assessmentNot HiringNo open roles listed right now. Follow GenDx to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Phase 3
Clinical Trials (1)
NCT06472245Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Phase 3Help build intelligence for GenDx
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.